{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:15:24Z","timestamp":1784128524013,"version":"3.55.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03234-x","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T10:11:10Z","timestamp":1766743870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of Aldo-Keto reductase family 1 member C in cancer progression: a special focus on the role of AKR1C1 in pancreatic cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Degao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"key":"3234_CR1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cbi.2014.09.024","volume":"234","author":"TM Penning","year":"2015","unstructured":"Penning TM. The aldo-keto reductases (AKRs): overview. Chem Biol Interact. 2015;234:236\u201346.","journal-title":"Chem Biol Interact"},{"issue":"3","key":"3234_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4149\/neo_2023_230206N66","volume":"70","author":"Z Wang","year":"2023","unstructured":"Wang Z, et al. Function, drug resistance and prognostic effect of AKR1C2 in human cancer. Neoplasma. 2023;70(3):319\u201332.","journal-title":"Neoplasma"},{"key":"3234_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109746","volume":"351","author":"X Chu","year":"2022","unstructured":"Chu X, et al. Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): functions, regulation, and structural insights of inhibitors. Chem Biol Interact. 2022;351:109746.","journal-title":"Chem Biol Interact"},{"key":"3234_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0009-2797(02)00193-X","volume":"143\u2013144","author":"D Hyndman","year":"2003","unstructured":"Hyndman D, et al. The aldo-keto reductase superfamily homepage. Chem Biol Interact. 2003;143\u2013144:621\u201331.","journal-title":"Chem Biol Interact"},{"issue":"Pt 1","key":"3234_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1042\/bj3510067","volume":"351","author":"TM Penning","year":"2000","unstructured":"Penning TM, et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J. 2000;351(Pt 1):67\u201377.","journal-title":"Biochem J"},{"issue":"1","key":"3234_CR6","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1186\/s12885-022-09924-3","volume":"22","author":"SS Guo","year":"2022","unstructured":"Guo SS, et al. Prognostic significance of AKR1C4 and the advantage of combining EBV DNA to stratify patients at high risk of locoregional recurrence of nasopharyngeal carcinoma. BMC Cancer. 2022;22(1):880.","journal-title":"BMC Cancer"},{"issue":"4","key":"3234_CR7","first-page":"278","volume":"5","author":"VL Miller","year":"2012","unstructured":"Miller VL, et al. Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma. Int J Clin Exp Pathol. 2012;5(4):278\u201389.","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"3234_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1210\/er.2018-00089","volume":"40","author":"TM Penning","year":"2019","unstructured":"Penning TM, Wangtrakuldee P, Auchus RJ. Structural and functional biology of Aldo-Keto reductase Steroid-Transforming enzymes. Endocr Rev. 2019;40(2):447\u201375.","journal-title":"Endocr Rev"},{"key":"3234_CR9","doi-asserted-by":"crossref","unstructured":"Jez JM et al. Comparative anatomy of the aldo-keto reductase superfamily. Biochem J, 1997. 326 (Pt 3)(Pt 3): pp. 625\u2009\u2013\u200936.","DOI":"10.1042\/bj3260625"},{"key":"3234_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.steroids.2013.10.012","volume":"79","author":"TL Ri\u017ener","year":"2014","unstructured":"Ri\u017ener TL, Penning TM. Role of aldo\u2013keto reductase family 1 (AKR1) enzymes in human steroid metabolism. Steroids. 2014;79:49\u201363.","journal-title":"Steroids"},{"issue":"3","key":"3234_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/jpm10030124","volume":"10","author":"A Franko","year":"2020","unstructured":"Franko A, et al. Transcript levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) are increased in prostate tissue of patients with type 2 diabetes. J Pers Med. 2020;10(3):124.","journal-title":"J Pers Med"},{"issue":"2","key":"3234_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2443.2000.00310.x","volume":"5","author":"M Nishizawa","year":"2000","unstructured":"Nishizawa M, et al. Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells. 2000;5(2):111\u201325.","journal-title":"Genes Cells"},{"issue":"1\u20132","key":"3234_CR13","first-page":"74","volume":"301","author":"T vSmuc","year":"2009","unstructured":"vSmuc T, Rizner TL. Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol. 2009;301(1\u20132):74\u201382.","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"3234_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ajhg.2011.06.009","volume":"89","author":"CE Fl\u00fcck","year":"2011","unstructured":"Fl\u00fcck CE, et al. Why boys will be boys: two pathways of fetal testicular androgen biosynthesis are needed for male sexual differentiation. Am J Hum Genet. 2011;89(2):201\u201318.","journal-title":"Am J Hum Genet"},{"issue":"1\u20132","key":"3234_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.mce.2005.10.009","volume":"248","author":"TL Rizner","year":"2006","unstructured":"Rizner TL, et al. AKR1C1 and AKR1C3 May determine progesterone and Estrogen ratios in endometrial cancer. Mol Cell Endocrinol. 2006;248(1\u20132):126\u201335.","journal-title":"Mol Cell Endocrinol"},{"issue":"13\u201314","key":"3234_CR16","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.steroids.2004.09.014","volume":"69","author":"HK Lin","year":"2004","unstructured":"Lin HK, et al. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase\/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids. 2004;69(13\u201314):795\u2013801.","journal-title":"Steroids"},{"key":"3234_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2407-4-27","volume":"4","author":"MJ Lewis","year":"2004","unstructured":"Lewis MJ, Wiebe JP, Heathcote JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer. 2004;4:27.","journal-title":"BMC Cancer"},{"issue":"1","key":"3234_CR18","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/s41598-022-05785-9","volume":"12","author":"S Badmann","year":"2022","unstructured":"Badmann S, et al. AKR1C1\/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin. Sci Rep. 2022;12(1):1862.","journal-title":"Sci Rep"},{"key":"3234_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-672","volume":"10","author":"MG Dozmorov","year":"2010","unstructured":"Dozmorov MG, et al. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression. BMC Cancer. 2010;10:672.","journal-title":"BMC Cancer"},{"issue":"1","key":"3234_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1186\/s12935-021-02267-2","volume":"21","author":"F Huang","year":"2021","unstructured":"Huang F, et al. Ferroptosis-related gene AKR1C1 predicts the prognosis of non-small cell lung cancer. Cancer Cell Int. 2021;21(1):567.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"3234_CR21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/path.2039","volume":"210","author":"M Woenckhaus","year":"2006","unstructured":"Woenckhaus M, et al. Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers. J Pathol. 2006;210(2):192\u2013204.","journal-title":"J Pathol"},{"key":"3234_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1476-4598-6-75","volume":"6","author":"DC Seo","year":"2007","unstructured":"Seo DC, et al. Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells. Mol Cancer. 2007;6:75.","journal-title":"Mol Cancer"},{"issue":"6","key":"3234_CR23","first-page":"2727","volume":"61","author":"NY Hsu","year":"2001","unstructured":"Hsu NY, et al. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res. 2001;61(6):2727\u201331.","journal-title":"Cancer Res"},{"issue":"2","key":"3234_CR24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s10620-008-0350-7","volume":"54","author":"HC Chang","year":"2009","unstructured":"Chang HC, et al. Overexpression of dihydrodiol dehydrogenase as a prognostic marker in resected gastric cancer patients. Dig Dis Sci. 2009;54(2):342\u20137.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"3234_CR25","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1158\/0008-5472.CAN-20-2480","volume":"81","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, et al. A positive feedback loop of AKR1C3-mediated activation of NF-\u03baB and STAT3 facilitates proliferation and metastasis in hepatocellular carcinoma. Cancer Res. 2021;81(5):1361\u201374.","journal-title":"Cancer Res"},{"issue":"6","key":"3234_CR26","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/mc.23527","volume":"62","author":"J Chen","year":"2023","unstructured":"Chen J, et al. AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP\/SLC7A11 signaling pathway. Mol Carcinog. 2023;62(6):833\u201344.","journal-title":"Mol Carcinog"},{"issue":"1","key":"3234_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.32604\/or.2023.030975","volume":"32","author":"KS Jeng","year":"2023","unstructured":"Jeng KS, et al. Aldo-keto reductase family member C3 (AKR1C3) promotes hepatocellular carcinoma cell growth by producing prostaglandin F2\u03b1. Oncol Res. 2023;32(1):163\u201374.","journal-title":"Oncol Res"},{"issue":"31","key":"3234_CR28","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1038\/s41388-022-02379-7","volume":"41","author":"D Pan","year":"2022","unstructured":"Pan D, et al. AKR1C3 regulated by NRF2\/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma. Oncogene. 2022;41(31):3846\u201358.","journal-title":"Oncogene"},{"issue":"2","key":"3234_CR29","first-page":"305","volume":"17","author":"HL Tai","year":"2007","unstructured":"Tai HL, et al. Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer. Oncol Rep. 2007;17(2):305\u201311.","journal-title":"Oncol Rep"},{"key":"3234_CR30","doi-asserted-by":"publisher","first-page":"34625","DOI":"10.1038\/srep34625","volume":"6","author":"R Matsumoto","year":"2016","unstructured":"Matsumoto R, et al. Aldo-keto reductase 1C1 induced by interleukin-1\u03b2 mediates the invasive potential and drug resistance of metastatic bladder cancer cells. Sci Rep. 2016;6:34625.","journal-title":"Sci Rep"},{"key":"3234_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fphar.2012.00034","volume":"3","author":"TL Ri\u017ener","year":"2012","unstructured":"Ri\u017ener TL. Enzymes of the AKR1B and AKR1C subfamilies and uterine diseases. Front Pharmacol. 2012;3:34.","journal-title":"Front Pharmacol"},{"issue":"4","key":"3234_CR32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nbt.3772","volume":"35","author":"J Vivian","year":"2017","unstructured":"Vivian J, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35(4):314\u20136.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"3234_CR33","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cell.2018.03.059","volume":"173","author":"A Blum","year":"2018","unstructured":"Blum A, et al. Snapshot: TCGA-analyzed tumors. Cell. 2018;173(2):530.","journal-title":"Cell"},{"issue":"8","key":"3234_CR34","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938\u201345.","journal-title":"Nat Med"},{"issue":"10","key":"3234_CR35","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138.","journal-title":"Nat Med"},{"issue":"6","key":"3234_CR36","doi-asserted-by":"publisher","first-page":"bbab260","DOI":"10.1093\/bib\/bbab260","volume":"22","author":"D Maeser","year":"2021","unstructured":"Maeser D, et al. OncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6):bbab260.","journal-title":"Brief Bioinform"},{"issue":"D1","key":"3234_CR37","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2012","unstructured":"Yang W, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2012;41(D1):D955\u201361.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"3234_CR38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.21147\/j.issn.1000-9604.2022.03.05","volume":"34","author":"Health Commission Of The Prc, N.","year":"2022","unstructured":"Health Commission Of The Prc, N. National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):238\u201355.","journal-title":"Chin J Cancer Res"},{"key":"3234_CR39","first-page":"53","volume":"7","author":"H Tian","year":"2016","unstructured":"Tian H, et al. High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells. Lung Cancer (Auckl). 2016;7:53\u201361.","journal-title":"Lung Cancer (Auckl)"},{"issue":"5","key":"3234_CR40","first-page":"6445","volume":"16","author":"W Jiang","year":"2018","unstructured":"Jiang W, et al. Wentilactone A induces cell apoptosis by targeting AKR1C1 gene via the IGF-1R\/IRS1\/PI3K\/AKT\/Nrf2\/FLIP\/Caspase-3 signaling pathway in small cell lung cancer. Oncol Lett. 2018;16(5):6445\u201357.","journal-title":"Oncol Lett"},{"key":"3234_CR41","doi-asserted-by":"publisher","first-page":"847906","DOI":"10.3389\/fphar.2022.847906","volume":"13","author":"Z Fu","year":"2022","unstructured":"Fu Z, et al. Natural product Alantolactone targeting AKR1C1 suppresses cell proliferation and metastasis in non-small-cell lung cancer. Front Pharmacol. 2022;13:847906.","journal-title":"Front Pharmacol"},{"key":"3234_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101421","volume":"20","author":"LL Chang","year":"2022","unstructured":"Chang LL, et al. AKR1C1 promotes non-small cell lung cancer proliferation via crosstalk between HIF-1\u03b1 and metabolic reprogramming. Transl Oncol. 2022;20:101421.","journal-title":"Transl Oncol"},{"issue":"3","key":"3234_CR43","doi-asserted-by":"publisher","first-page":"676","DOI":"10.7150\/thno.21463","volume":"8","author":"H Zhu","year":"2018","unstructured":"Zhu H, et al. AKR1C1 activates STAT3 to promote the metastasis of non-small cell lung cancer. Theranostics. 2018;8(3):676\u201392.","journal-title":"Theranostics"},{"issue":"5","key":"3234_CR44","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.7150\/thno.39151","volume":"10","author":"H Zhu","year":"2020","unstructured":"Zhu H, et al. The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in non-small cell lung cancer. Theranostics. 2020;10(5):2188\u2013200.","journal-title":"Theranostics"},{"issue":"1","key":"3234_CR45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13046-019-1256-2","volume":"38","author":"WM Chang","year":"2019","unstructured":"Chang WM, et al. AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1\/3 signaling pathway. J Exp Clin Cancer Res. 2019;38(1):245.","journal-title":"J Exp Clin Cancer Res"},{"key":"3234_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.677678","volume":"11","author":"Y Gao","year":"2021","unstructured":"Gao Y, et al. Avasimibe dampens cholangiocarcinoma progression by inhibiting FoxM1-AKR1C1 signaling. Front Oncol. 2021;11:677678.","journal-title":"Front Oncol"},{"issue":"13","key":"3234_CR47","doi-asserted-by":"publisher","first-page":"11600","DOI":"10.18632\/oncotarget.3417","volume":"6","author":"H Yun","year":"2015","unstructured":"Yun H, et al. Activation of AKR1C1\/ER\u03b2 induces apoptosis by downregulation of c-FLIP in prostate cancer cells: a prospective therapeutic opportunity. Oncotarget. 2015;6(13):11600\u201313.","journal-title":"Oncotarget"},{"issue":"12","key":"3234_CR48","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41374-022-00816-5","volume":"102","author":"M Hu","year":"2022","unstructured":"Hu M, et al. Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism. Lab Invest. 2022;102(12):1335\u201345.","journal-title":"Lab Invest"},{"issue":"12","key":"3234_CR49","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41419-019-2143-7","volume":"10","author":"M Gagliardi","year":"2019","unstructured":"Gagliardi M, et al. Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis. Cell Death Dis. 2019;10(12):902.","journal-title":"Cell Death Dis"},{"issue":"4","key":"3234_CR50","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bjh.16253","volume":"189","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, et al. Upregulation of AKR1C1 in mesenchymal stromal cells promotes the survival of acute myeloid leukaemia cells. Br J Haematol. 2020;189(4):694\u2013706.","journal-title":"Br J Haematol"},{"issue":"4","key":"3234_CR51","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/pros.10192","volume":"54","author":"Q Ji","year":"2003","unstructured":"Ji Q, et al. Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. Prostate. 2003;54(4):275\u201389.","journal-title":"Prostate"},{"issue":"1\u20132","key":"3234_CR52","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mce.2008.04.004","volume":"289","author":"S Wang","year":"2008","unstructured":"Wang S, et al. AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K\/Akt proliferative signaling pathway in human prostate cancer cells. Mol Cell Endocrinol. 2008;289(1\u20132):60\u20136.","journal-title":"Mol Cell Endocrinol"},{"issue":"17","key":"3234_CR53","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1111\/jcmm.15604","volume":"24","author":"ZF Zhang","year":"2020","unstructured":"Zhang ZF, et al. AKR1C2 acts as a targetable oncogene in esophageal squamous cell carcinoma via activating PI3K\/AKT signaling pathway. J Cell Mol Med. 2020;24(17):9999\u201310012.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"3234_CR54","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3727\/096504015X14386062091352","volume":"22","author":"C Li","year":"2014","unstructured":"Li C, et al. AEG-1 promotes metastasis through downstream AKR1C2 and NF1 in liver cancer. Oncol Res. 2014;22(4):203\u201311.","journal-title":"Oncol Res"},{"issue":"1","key":"3234_CR55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/1087057115603310","volume":"21","author":"C Li","year":"2016","unstructured":"Li C, et al. High-content functional screening of AEG-1 and AKR1C2 for the promotion of metastasis in liver cancer. J Biomol Screen. 2016;21(1):101\u20137.","journal-title":"J Biomol Screen"},{"key":"3234_CR56","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.carbpol.2013.11.016","volume":"102","author":"C Li","year":"2014","unstructured":"Li C, et al. Panax ginseng polysaccharide induces apoptosis by targeting Twist\/AKR1C2\/NF-1 pathway in human gastric cancer. Carbohydr Polym. 2014;102:103\u20139.","journal-title":"Carbohydr Polym"},{"issue":"1","key":"3234_CR57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4048\/jbc.2023.26.e1","volume":"26","author":"S Li","year":"2023","unstructured":"Li S, et al. AKR1C2 promotes metastasis and regulates the molecular features of luminal androgen receptor subtype in triple negative breast cancer cells. J Breast Cancer. 2023;26(1):60\u201376.","journal-title":"J Breast Cancer"},{"issue":"4","key":"3234_CR58","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.3390\/ijms24043872","volume":"24","author":"M Liu","year":"2023","unstructured":"Liu M, et al. SRSF3-mediated Ki67 exon 7-inclusion promotes head and neck squamous cell carcinoma progression via repressing AKR1C2. Int J Mol Sci. 2023;24(4):3872.","journal-title":"Int J Mol Sci"},{"key":"3234_CR59","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.mce.2015.07.008","volume":"413","author":"T Yoda","year":"2015","unstructured":"Yoda T, et al. 11\u03b2-prostaglandin F2\u03b1, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer. Mol Cell Endocrinol. 2015;413:236\u201347.","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"3234_CR60","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jsbmb.2009.12.009","volume":"118","author":"MC Byrns","year":"2010","unstructured":"Byrns MC, et al. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. J Steroid Biochem Mol Biol. 2010;118(3):177\u201387.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"18","key":"3234_CR61","doi-asserted-by":"publisher","first-page":"10396","DOI":"10.1021\/acs.jmedchem.0c00939","volume":"63","author":"S Endo","year":"2020","unstructured":"Endo S, et al. Development of novel AKR1C3 inhibitors as new potential treatment for castration-resistant prostate cancer. J Med Chem. 2020;63(18):10396\u2013411.","journal-title":"J Med Chem"},{"issue":"9","key":"3234_CR62","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1158\/2767-9764.CRC-23-0235","volume":"3","author":"AJ Detlefsen","year":"2023","unstructured":"Detlefsen AJ, et al. AKR1C3 converts castrate and post-abiraterone DHEA-S into testosterone to stimulate growth of prostate cancer cells via 5-androstene-3\u03b2,17\u03b2-diol. Cancer Res Commun. 2023;3(9):1888\u201398.","journal-title":"Cancer Res Commun"},{"issue":"10","key":"3234_CR63","doi-asserted-by":"publisher","first-page":"472.e11","DOI":"10.1016\/j.urolonc.2018.07.005","volume":"36","author":"B Wang","year":"2018","unstructured":"Wang B, et al. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling. Urol Oncol. 2018;36(10):472.e11-472.e20.","journal-title":"Urol Oncol"},{"issue":"2","key":"3234_CR64","doi-asserted-by":"publisher","first-page":"bqz042","DOI":"10.1210\/endocr\/bqz042","volume":"161","author":"S Park","year":"2020","unstructured":"Park S, et al. Inhibitory interplay of SULT2B1b sulfotransferase with AKR1C3 aldo-keto reductase in prostate cancer. Endocrinology. 2020;161(2):bqz042.","journal-title":"Endocrinology"},{"issue":"20","key":"3234_CR65","doi-asserted-by":"publisher","first-page":"12032","DOI":"10.1111\/jcmm.15831","volume":"24","author":"B Wang","year":"2020","unstructured":"Wang B, et al. The AKR1C3\/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression. J Cell Mol Med. 2020;24(20):12032\u201343.","journal-title":"J Cell Mol Med"},{"key":"3234_CR66","doi-asserted-by":"crossref","unstructured":"Yu X et al. Inhibition of castration-resistant prostate cancer growth by genistein through suppression of AKR1C3. Food Nutr Res, 2023. 67.","DOI":"10.29219\/fnr.v67.9024"},{"issue":"11","key":"3234_CR67","doi-asserted-by":"publisher","first-page":"10784","DOI":"10.1074\/jbc.M313308200","volume":"279","author":"S Steckelbroeck","year":"2004","unstructured":"Steckelbroeck S, et al. Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J Biol Chem. 2004;279(11):10784\u201395.","journal-title":"J Biol Chem"},{"issue":"2","key":"3234_CR68","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ejca.2006.09.001","volume":"43","author":"I Martinez","year":"2007","unstructured":"Martinez I, et al. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer. 2007;43(2):415\u201332.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3234_CR69","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/cr.2010.183","volume":"21","author":"G He","year":"2011","unstructured":"He G, Karin M. STAT3 - key players in liver inflammation and cancer. Cell Res. 2011;21(1):159\u201368.","journal-title":"Cell Res"},{"issue":"1","key":"3234_CR70","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1600-065X.2012.01099.x","volume":"246","author":"JA DiDonato","year":"2012","unstructured":"DiDonato JA, Mercurio F, Karin M. NF-\u03baB and the link between inflammation and cancer. Immunol Rev. 2012;246(1):379\u2013400.","journal-title":"Immunol Rev"},{"issue":"8","key":"3234_CR71","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/exd.12468","volume":"23","author":"A Mantel","year":"2014","unstructured":"Mantel A, et al. Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism. Exp Dermatol. 2014;23(8):573\u20138.","journal-title":"Exp Dermatol"},{"issue":"2","key":"3234_CR72","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ygyno.2013.11.032","volume":"132","author":"CH Wu","year":"2014","unstructured":"Wu CH, et al. Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix. Gynecol Oncol. 2014;132(2):474\u201382.","journal-title":"Gynecol Oncol"},{"key":"3234_CR73","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00280-024-04685-1","volume":"94","author":"L Wang","year":"2024","unstructured":"Wang L, Lv C, Liu X. AKR1C4 regulates the sensitivity of colorectal cancer cells to chemotherapy through ferroptosis modulation. Cancer Chemother Pharmacol. 2024;94:373\u2013385.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"3234_CR74","first-page":"4515","volume":"18","author":"SF Zhao","year":"2019","unstructured":"Zhao SF, et al. AKR1C1-3, notably AKR1C3, are distinct biomarkers for liver cancer diagnosis and prognosis: database mining in malignancies. Oncol Lett. 2019;18(5):4515\u201322.","journal-title":"Oncol Lett"},{"issue":"3","key":"3234_CR75","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.18632\/aging.202380","volume":"13","author":"P Zhu","year":"2021","unstructured":"Zhu P, et al. Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma. Aging. 2021;13(3):4138\u201356.","journal-title":"Aging"},{"issue":"10","key":"3234_CR76","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1002\/ijc.31954","volume":"144","author":"CU Huebbers","year":"2019","unstructured":"Huebbers CU, et al. Upregulation of AKR1C1 and AKR1C3 expression in OPSCC with integrated HPV16 and HPV-negative tumors is an indicator of poor prognosis. Int J Cancer. 2019;144(10):2465\u201377.","journal-title":"Int J Cancer"},{"issue":"2","key":"3234_CR77","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s13402-020-00571-z","volume":"44","author":"C Peraldo-Neia","year":"2021","unstructured":"Peraldo-Neia C, et al. AKR1C3 is a biomarker and druggable target for oropharyngeal tumors. Cell Oncol (Dordr). 2021;44(2):357\u201372.","journal-title":"Cell Oncol (Dordr)"},{"issue":"11","key":"3234_CR78","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1111\/jcmm.15291","volume":"24","author":"C Zhou","year":"2020","unstructured":"Zhou C, et al. Loss of AKR1C1 is a good prognostic factor in advanced NPC cases and increases chemosensitivity to cisplatin in NPC cells. J Cell Mol Med. 2020;24(11):6438\u201347.","journal-title":"J Cell Mol Med"},{"issue":"11","key":"3234_CR79","doi-asserted-by":"publisher","first-page":"e870","DOI":"10.1093\/oncolo\/oyac177","volume":"27","author":"S Zhu","year":"2022","unstructured":"Zhu S, et al. Plasma exosomal AKR1C3 mRNA expression is a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer. Oncologist. 2022;27(11):e870\u20137.","journal-title":"Oncologist"},{"issue":"16","key":"3234_CR80","doi-asserted-by":"publisher","first-page":"21542","DOI":"10.18632\/oncotarget.7775","volume":"7","author":"W Li","year":"2016","unstructured":"Li W, et al. The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoate induced esophageal squamous cell carcinoma cell death. Oncotarget. 2016;7(16):21542\u201355.","journal-title":"Oncotarget"},{"issue":"3","key":"3234_CR81","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1158\/0008-5472.CAN-06-1593","volume":"67","author":"Q Ji","year":"2007","unstructured":"Ji Q, et al. Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Res. 2007;67(3):1361\u20139.","journal-title":"Cancer Res"},{"issue":"15","key":"3234_CR82","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869\u201383.","journal-title":"Oncogene"},{"issue":"1\u20133","key":"3234_CR83","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cbi.2012.09.024","volume":"202","author":"T Matsunaga","year":"2013","unstructured":"Matsunaga T, et al. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers. Chem Biol Interact. 2013;202(1\u20133):234\u201342.","journal-title":"Chem Biol Interact"},{"issue":"22","key":"3234_CR84","doi-asserted-by":"publisher","first-page":"12512","DOI":"10.3390\/ijms222212512","volume":"22","author":"NLL Phoo","year":"2021","unstructured":"Phoo NLL, et al. Transcriptomic profiling reveals AKR1C1 and AKR1C3 mediate cisplatin resistance in signet ring cell gastric carcinoma via autophagic cell death. Int J Mol Sci. 2021;22(22):12512.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3234_CR85","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1002\/ijc.22402","volume":"120","author":"HW Wang","year":"2007","unstructured":"Wang HW, et al. Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin. Int J Cancer. 2007;120(9):2019\u201327.","journal-title":"Int J Cancer"},{"issue":"4","key":"3234_CR86","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00280-004-0815-0","volume":"54","author":"HB Deng","year":"2004","unstructured":"Deng HB, et al. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Cancer Chemother Pharmacol. 2004;54(4):301\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3234_CR87","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41420-024-01892-w","volume":"10","author":"S Zhen","year":"2024","unstructured":"Zhen S, et al. NEAT1_1 confers gefitinib resistance in lung adenocarcinoma through promoting AKR1C1-mediated ferroptosis defence. Cell Death Discov. 2024;10(1):131.","journal-title":"Cell Death Discov"},{"issue":"3","key":"3234_CR88","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.21037\/jgo-23-277","volume":"14","author":"C Gao","year":"2023","unstructured":"Gao C, et al. AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma. J Gastrointest Oncol. 2023;14(3):1412\u201333.","journal-title":"J Gastrointest Oncol"},{"issue":"9","key":"3234_CR89","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1593\/neo.10526","volume":"12","author":"B Le Calv\u00e9","year":"2010","unstructured":"Le Calv\u00e9 B, et al. Long-term in vitro treatment of human glioblastoma cells with Temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia. 2010;12(9):727\u201339.","journal-title":"Neoplasia"},{"issue":"8","key":"3234_CR90","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1097\/CAD.0000000000000112","volume":"25","author":"T Matsunaga","year":"2014","unstructured":"Matsunaga T, et al. Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of Daunorubicin chemotherapy for leukemic U937 cells. Anticancer Drugs. 2014;25(8):868\u201377.","journal-title":"Anticancer Drugs"},{"issue":"12","key":"3234_CR91","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s41419-022-05507-z","volume":"13","author":"X Ma","year":"2022","unstructured":"Ma X, et al. ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by targeting MGLL. Cell Death Dis. 2022;13(12):1067.","journal-title":"Cell Death Dis"},{"issue":"9","key":"3234_CR92","doi-asserted-by":"publisher","first-page":"10363","DOI":"10.18632\/oncotarget.7004","volume":"7","author":"Y Wang","year":"2016","unstructured":"Wang Y, et al. Mechanism of progestin resistance in endometrial precancer\/cancer through Nrf2-AKR1C1 pathway. Oncotarget. 2016;7(9):10363\u201372.","journal-title":"Oncotarget"},{"issue":"3","key":"3234_CR93","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3892\/ol.2013.1768","volume":"7","author":"A Shirato","year":"2014","unstructured":"Shirato A, et al. Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells. Oncol Lett. 2014;7(3):674\u20138.","journal-title":"Oncol Lett"},{"issue":"2","key":"3234_CR94","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.lungcan.2012.03.016","volume":"77","author":"P Kuang","year":"2012","unstructured":"Kuang P, et al. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients. Lung Cancer. 2012;77(2):427\u201332.","journal-title":"Lung Cancer"},{"key":"3234_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102027","volume":"47","author":"W Liu","year":"2024","unstructured":"Liu W, et al. AKR1C3 promotes progression and mediates therapeutic resistance by inducing epithelial-mesenchymal transition and angiogenesis in small cell lung cancer. Transl Oncol. 2024;47:102027.","journal-title":"Transl Oncol"},{"issue":"14","key":"3234_CR96","doi-asserted-by":"publisher","first-page":"9537","DOI":"10.1021\/acs.jmedchem.3c00213","volume":"66","author":"S He","year":"2023","unstructured":"He S, et al. Development of biaryl-containing Aldo-Keto Reductase 1C3 (AKR1C3) inhibitors for reversing AKR1C3-mediated drug resistance in cancer treatment. J Med Chem. 2023;66(14):9537\u201360.","journal-title":"J Med Chem"},{"issue":"7","key":"3234_CR97","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1021\/acs.jmedchem.9b00090","volume":"62","author":"K Verma","year":"2019","unstructured":"Verma K, et al. Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. J Med Chem. 2019;62(7):3590\u2013616.","journal-title":"J Med Chem"},{"issue":"8","key":"3234_CR98","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1021\/acsmedchemlett.6b00163","volume":"7","author":"K Verma","year":"2016","unstructured":"Verma K, et al. Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines. ACS Med Chem Lett. 2016;7(8):774\u20139.","journal-title":"ACS Med Chem Lett"},{"issue":"11","key":"3234_CR99","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.7150\/ijms.9239","volume":"11","author":"J Zhao","year":"2014","unstructured":"Zhao J, et al. AKR1C3 overexpression mediates methotrexate resistance in choriocarcinoma cells. Int J Med Sci. 2014;11(11):1089\u201397.","journal-title":"Int J Med Sci"},{"issue":"3","key":"3234_CR100","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrclinonc.2009.236","volume":"7","author":"A Stathis","year":"2010","unstructured":"Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7(3):163\u201372.","journal-title":"Nat Rev Clin Oncol"},{"key":"3234_CR101","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1476-4598-10-37","volume":"10","author":"A Lister","year":"2011","unstructured":"Lister A, et al. Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Mol Cancer. 2011;10:37.","journal-title":"Mol Cancer"},{"issue":"9","key":"3234_CR102","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/nrc1451","volume":"4","author":"J Bernier","year":"2004","unstructured":"Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer. 2004;4(9):737\u201347.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3234_CR103","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/09553009414550041","volume":"65","author":"PA Riley","year":"1994","unstructured":"Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol. 1994;65(1):27\u201333.","journal-title":"Int J Radiat Biol"},{"issue":"11","key":"3234_CR104","doi-asserted-by":"publisher","first-page":"e111911","DOI":"10.1371\/journal.pone.0111911","volume":"9","author":"W Xiong","year":"2014","unstructured":"Xiong W, et al. Elevated expression of AKR1C3 increases resistance of cancer cells to ionizing radiation via modulation of oxidative stress. PLoS One. 2014;9(11):e111911.","journal-title":"PLoS One"},{"key":"3234_CR105","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.2147\/CMAR.S166942","volume":"10","author":"X Li","year":"2018","unstructured":"Li X, et al. Methyl jasmonate enhances the radiation sensitivity of esophageal carcinoma cells by inhibiting the 11-ketoprostaglandin reductase activity of AKR1C3. Cancer Manag Res. 2018;10:3149\u201358.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"3234_CR106","first-page":"802","volume":"26","author":"W Xiong","year":"2021","unstructured":"Xiong W, Hu XHW. AKR1C3 and \u03b2-catenin expression in non-small cell lung cancer and relationship with radiation resistance. J Buon. 2021;26(3):802\u201311.","journal-title":"J Buon"},{"issue":"4","key":"3234_CR107","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/cgt.2013.15","volume":"20","author":"L Xie","year":"2013","unstructured":"Xie L, et al. Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer. Cancer Gene Ther. 2013;20(4):260\u20136.","journal-title":"Cancer Gene Ther"},{"issue":"30","key":"3234_CR108","doi-asserted-by":"publisher","first-page":"48050","DOI":"10.18632\/oncotarget.10347","volume":"7","author":"SQ Sun","year":"2016","unstructured":"Sun SQ, et al. Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation. Oncotarget. 2016;7(30):48050\u20138.","journal-title":"Oncotarget"},{"issue":"42","key":"3234_CR109","doi-asserted-by":"publisher","first-page":"6524","DOI":"10.1038\/sj.onc.1206757","volume":"22","author":"T Bogenrieder","year":"2003","unstructured":"Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003;22(42):6524\u201336.","journal-title":"Oncogene"},{"issue":"14","key":"3234_CR110","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1158\/0008-5472.CAN-10-1040","volume":"70","author":"JE Talmadge","year":"2010","unstructured":"Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010;70(14):5649\u201369.","journal-title":"Cancer Res"},{"key":"3234_CR111","doi-asserted-by":"publisher","first-page":"6189","DOI":"10.2147\/IJGM.S329031","volume":"14","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, et al. Evaluation of Ferroptosis-related gene AKR1C1 as a novel biomarker associated with the immune microenvironment and prognosis in breast cancer. Int J Gen Med. 2021;14:6189\u2013200.","journal-title":"Int J Gen Med"},{"issue":"10","key":"3234_CR112","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41419-023-06220-1","volume":"14","author":"KG Zhu","year":"2023","unstructured":"Zhu KG, et al. The microprotein encoded by exosomal lncAKR1C2 promotes gastric cancer lymph node metastasis by regulating fatty acid metabolism. Cell Death Dis. 2023;14(10):708.","journal-title":"Cell Death Dis"},{"issue":"3","key":"3234_CR113","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s10147-015-0924-2","volume":"21","author":"A Wenners","year":"2016","unstructured":"Wenners A, et al. Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer. Int J Clin Oncol. 2016;21(3):548\u201356.","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"3234_CR114","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/biom13050736","volume":"13","author":"Z Wu","year":"2023","unstructured":"Wu Z, et al. Epigenetic and tumor microenvironment for prognosis of patients with gastric cancer. Biomolecules. 2023;13(5):736.","journal-title":"Biomolecules"},{"issue":"5","key":"3234_CR115","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.3390\/ijms24054513","volume":"24","author":"X Cui","year":"2023","unstructured":"Cui X, et al. Establishing a proteomics-based signature of AKR1C3-related genes for predicting the prognosis of prostate cancer. Int J Mol Sci. 2023;24(5):4513.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3234_CR116","first-page":"176","volume":"12","author":"TT Le","year":"2022","unstructured":"Le TT, et al. The ADAM9\/UBN2\/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancer. Am J Cancer Res. 2022;12(1):176\u201397.","journal-title":"Am J Cancer Res"},{"issue":"1\u20133","key":"3234_CR117","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.cbi.2008.10.024","volume":"178","author":"MC Byrns","year":"2009","unstructured":"Byrns MC, Penning TM. Type 5 17beta-hydroxysteroid dehydrogenase\/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009;178(1\u20133):221\u20137.","journal-title":"Chem Biol Interact"},{"key":"3234_CR118","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3389\/fphar.2017.00119","volume":"8","author":"CM Zeng","year":"2017","unstructured":"Zeng CM, et al. Aldo-keto reductase AKR1C1-AKR1C4: functions, regulation, and intervention for anti-cancer therapy. Front Pharmacol. 2017;8:119.","journal-title":"Front Pharmacol"},{"issue":"11","key":"3234_CR119","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.ejmech.2010.08.052","volume":"45","author":"O El-Kabbani","year":"2010","unstructured":"El-Kabbani O, et al. Structure-based optimization and biological evaluation of human 20\u03b1-hydroxysteroid dehydrogenase (AKR1C1) salicylic acid-based inhibitors. Eur J Med Chem. 2010;45(11):5309\u201317.","journal-title":"Eur J Med Chem"},{"key":"3234_CR120","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3389\/fphys.2019.00833","volume":"10","author":"C Zeng","year":"2019","unstructured":"Zeng C, et al. Liquiritin, as a natural inhibitor of AKR1C1, could interfere with the progesterone metabolism. Front Physiol. 2019;10:833.","journal-title":"Front Physiol"},{"key":"3234_CR121","doi-asserted-by":"publisher","first-page":"920379","DOI":"10.3389\/fphar.2022.920379","volume":"13","author":"J Kljun","year":"2022","unstructured":"Kljun J, et al. Ruthenium complexes show potent inhibition of AKR1C1, AKR1C2, and AKR1C3 enzymes and anti-proliferative action against chemoresistant ovarian cancer cell line. Front Pharmacol. 2022;13:920379.","journal-title":"Front Pharmacol"},{"issue":"9","key":"3234_CR122","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-17-1023","volume":"17","author":"K Verma","year":"2018","unstructured":"Verma K, et al. AKR1C3 inhibitor KV-37 exhibits antineoplastic effects and potentiates enzalutamide in combination therapy in prostate adenocarcinoma cells. Mol Cancer Ther. 2018;17(9):1833\u201345.","journal-title":"Mol Cancer Ther"},{"key":"3234_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00159","volume":"4","author":"YD Yin","year":"2014","unstructured":"Yin YD, et al. The activity of SN33638, an inhibitor of AKR1C3, on testosterone and 17\u03b2-estradiol production and function in castration-resistant prostate cancer and ER-positive breast cancer. Front Oncol. 2014;4:159.","journal-title":"Front Oncol"},{"issue":"2","key":"3234_CR124","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.bcp.2007.09.008","volume":"75","author":"MC Byrns","year":"2008","unstructured":"Byrns MC, Steckelbroeck S, Penning TM. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol. 2008;75(2):484\u201393.","journal-title":"Biochem Pharmacol"},{"issue":"21","key":"3234_CR125","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202400081","volume":"19","author":"SK Jonnalagadda","year":"2024","unstructured":"Jonnalagadda SK. Coumarin-based aldo\u2010keto reductase family 1C (AKR1C) 2 and 3 inhibitors. ChemMedChem. 2024;19(21):e202400081.","journal-title":"ChemMedChem"},{"issue":"3","key":"3234_CR126","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.bmc.2013.12.050","volume":"22","author":"JU Flanagan","year":"2014","unstructured":"Flanagan JU, et al. Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-\u03b2-hydroxysteroid dehydrogenase (AKR1C3). Bioorg Med Chem. 2014;22(3):967\u201377.","journal-title":"Bioorg Med Chem"},{"key":"3234_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117413","volume":"289","author":"S Xing","year":"2025","unstructured":"Xing S, et al. Discovery of highly potent AKR1Cs pan-inhibitors as chemotherapeutic potentiators to restore breast cancer drug resistance. Eur J Med Chem. 2025;289:117413.","journal-title":"Eur J Med Chem"},{"issue":"10242","key":"3234_CR128","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, et al. Pancreatic cancer. Lancet. 2020;395(10242):2008\u201320.","journal-title":"Lancet"},{"issue":"11","key":"3234_CR129","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321.","journal-title":"Cancer Res"},{"issue":"3","key":"3234_CR130","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12029-015-9724-1","volume":"46","author":"A Carrato","year":"2015","unstructured":"Carrato A, et al. A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs. J Gastrointest Cancer. 2015;46(3):201\u201311.","journal-title":"J Gastrointest Cancer"},{"issue":"2","key":"3234_CR131","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","volume":"12","author":"P Sarantis","year":"2020","unstructured":"Sarantis P, et al. Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol. 2020;12(2):173\u201381.","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"3234_CR132","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1042\/bj3520685","volume":"352","author":"T Ohta","year":"2000","unstructured":"Ohta T, et al. Kinetic alteration of a human dihydrodiol\/3\u03b1-hydroxysteroid dehydrogenase isoenzyme, AKR1C4, by replacement of histidine-216 with tyrosine or phenylalanine. Biochem J. 2000;352(3):685\u201391.","journal-title":"Biochem J"},{"issue":"24","key":"3234_CR133","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.21.02616","volume":"40","author":"NA Ullman","year":"2022","unstructured":"Ullman NA, et al. Immunologic strategies in pancreatic cancer: making cold tumors hot. J Clin Oncol. 2022;40(24):2789\u2013805.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3234_CR134","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ags3.12225","volume":"3","author":"T Murakami","year":"2019","unstructured":"Murakami T, et al. Role of the tumor microenvironment in pancreatic cancer. Ann Gastroenterol Surg. 2019;3(2):130\u20137.","journal-title":"Ann Gastroenterol Surg"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03234-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03234-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03234-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T16:03:25Z","timestamp":1770393805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03234-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":134,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["3234"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03234-x","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data involving patients is available from public databases. We state this study not involving ethical issues.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"98"}}